Financial reports
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
Current reports
8-K
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 Feb 24
8-K
Other Events
9 Feb 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
8-K
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
9 Nov 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
8-K
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results
9 Aug 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
8-K
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results
10 May 23
Registration and prospectus
S-8
Registration of securities for employees
29 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
FWP
Free writing prospectus
7 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
S-3ASR
Automatic shelf registration
5 Feb 24
S-3
Shelf registration
9 Aug 23
424B5
Prospectus supplement for primary offering
8 May 23
424B5
Prospectus supplement for primary offering
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
3 May 23
S-8
Registration of securities for employees
15 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
DEFA14A
Additional proxy soliciting materials
6 Apr 21
DEF 14A
Definitive proxy
6 Apr 21
Other
EFFECT
Notice of effectiveness
16 Aug 23
UPLOAD
Letter from SEC
11 Aug 23
CORRESP
Correspondence with SEC
11 Aug 23
EFFECT
Notice of effectiveness
7 Sep 22
CORRESP
Correspondence with SEC
1 Sep 22
UPLOAD
Letter from SEC
30 Aug 22
EFFECT
Notice of effectiveness
18 Apr 22
CORRESP
Correspondence with SEC
13 Apr 22
UPLOAD
Letter from SEC
4 Apr 22
EFFECT
Notice of effectiveness
29 Oct 21
Ownership
4
Scott Bizily
18 Apr 24
4
Scott Bizily
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Scott Bizily
29 Mar 24
4
Scott Bizily
20 Mar 24
4
Scott Bizily
29 Feb 24
4
Scott Bizily
21 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Kirn David
14 Feb 24